Serum osteocalcin is associated with improved metabolic state via adiponectin in females versus testosterone in males. Gender specific nature of the bone-energy homeostasis axis

Bone

Volumn 57, Issue 1, 2013, Pages 98-104

  Buday, Barbara ^a   Pach, Ferenc Péter ^b   Literati Nagy, Botond ^a   Vitai, Marta ^a   Vecsei, Zsuzsa ^a   Koranyi, Laszlo ^a  

^a Drug Research Centre   (Hungary)

^b BAY ZOLTÁN NONPROFIT LTD FOR APPLIED RESEARCH   (Hungary)

Author keywords

Adiponectin; Insulin resistance; Osteocalcin; Testosterone

Indexed keywords

ADIPONECTIN; HEMOGLOBIN A1C; OSTEOCALCIN; TESTOSTERONE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE ENERGY HOMEOSTASIS AXIS; CONTROLLED STUDY; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

2DM; ACUTE INSULIN RESPONSE OF IVGTT; ADIPONECTIN; AIR; AREA UNDER THE CURVE; AUC; BFP; BMI; BODY FAT PERCENT; BODY MASS INDEX; CLAMP MEASURED MUSCLE GLUCOSE UPTAKE; CLAMP MEASURED WHOLE BODY GLUCOSE UPTAKE; DEXA; DUAL ENERGY X-RAY ABSORPTIOMETRY; FFA; FREE FATTY ACID; GI; GLUCOSE INTOLERANT; HOMA-IR; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; IFG; IGI; IGT; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANT; INSULIN RESISTANCE; INSULOGENIC INDEX OF IVGTT; INTRAVENOUS GLUCOSE TOLERANCE TEST; IVGTT; M1; M2; NGT; NORMAL GLUCOSE TOLERANT; OCN; OGTT; ORAL GLUCOSE TOLERANCE TEST; OSTEOCALCIN; TESTOSTERONE; TYPE 2 DIABETES MELLITUS; UCOCN; UNDERCARBOXYLATED OSTEOCALCIN; WAIST CIRCUMFERENCE; WC;

ADIPONECTIN; ADULT; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OSTEOCALCIN; TESTOSTERONE;

EID: 84882759617     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.07.018     Document Type: Article

References (35)

1. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130(3):456-469.
2. JA, Yu B.P., Jeon J.Y., Kim S.H. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 2008, 396:66-69.
3. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Kurioka S., Yano S., et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009, 94:45-49.
4. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94:827-832.
5. Fernández-Real J.M., Izquierdo M., Ortega F., Gorostiaga E., Gomez-Ambrosi J., Moreno-Navarrete J.M., et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009, 94:237-245.
6. Kindblom J.M., Ohlsson C., Ljunggren, Karlsson M.G., Tivesten A., Smith U., et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2008, 24:785-791.
7. Zhou M., Ma X., Li H., Pan X., Tang J., Gao Y., et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol 2009, 161:723-729.
8. Hwang Y.C., Jeong I.K., Ahn K.J., Chung H.Y. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 2009, 25:768-772.
9. Shea M.K., Gundberg C.M., Meigs J.B., Dallal G.E., Saltzman E., Yoshida M., et al. Gammacarboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr 2009, 90:1230-1235.
10. Pacini G., Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003, 17:305-322.
11. Hwang Y.C., Jeong L.K., Ahn K.J., Chung H.Y. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int 2012, 23(4):1337-1342.
12. Qury F., Sumara G., Sumara O., Ferron M., Chang H., Smith C.E., et al. Endocrine regulation of male fertility by the skeleton. Cell 2011, 144(5):796-809.
13. Kanazawa I., Tanaka K., Ogawa N., Yamauchi M., Yamaguchi T., Sugimoto T. Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus. Osteoporos Int 2013, 24(3):1115-1119.
14. Kirmani S., Atkinson E.J., Melton J.L., Lawrence B.R., Amin S., Khosla S. Relationship of testosterone and osteocalcin levels during growth. J Bone Min Res 2011, 26(9):2212-2216.
15. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssönen K., Tuomainen T.P., Valkonen V.P., et al. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes mellitus in middle-aged men. Diabetes Care 2004, 27:1036-1041.
16. Page S.T., Araujo A.B.., Travison T.G., Bremner W.J., McKinlay J.B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006, 91:843-850.
17. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., McKinlay J.B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000, 23:490-494.
18. Brand J.S., van der Tweel I., Grobbee D.E., Emmelot-Vonk M.H., van der Schouw Y.T. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011, 40(1):189-207.
19. Lee K, Sex-specific relationships between insulin resistance and bone mineral content in Korean adolescents. J Bone Miner Metab, doi:10.1007/s00774-012-0396-7.
20. ADA expert committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
21. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
22. Liaw A., Wiener M. Classification and regression by randomForest. R News 2000, 2(3):18-22.
23. Kursa M.B., Rudnicki W.R. Feature selection with the Boruta package. J Stat Softw Sep. 2010, 36(11):1-13.
24. Chen J.T., Hosoda K., Hasumi K., Ogata E., Shiraki M. Serum N-terminal osteocalcin is a good indicator for estimating responders to hormone replacement therapy in postmenopausal women. J Bone Miner Res 1996, 11(11):1784-1792.
25. Kanazawa I., Yamaguchi T., Tada Y., Yamauchi M., Yano S., Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 2011, 48(4):720-725. [Epub 2010 Dec 23].
26. Polgreen L.E., Jacobs D.R., Nathan B.M., Steinberger J., Moran A., Sinaiko A.R. Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity (Silver Spring) 2012, 11:2194-2201.
27. Riggs B.L., Wahner H.W., Dunn W.L., Mazess R.B., Offord K.P., Melton J.L. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 1981, 67:328-335.
28. Mazess R.B. On aging bone loss. Clin Orthop Relat Res 1982, 165:239-252.
29. Del Pino J., Martín-Gómez E., Martín-Rodríguez M., López-Sosa C., Cordero M., Lanchares J.L., et al. Influence of sex, age, and menopause in serum osteocalcin (BGP) levels. J Mol Med 1991, 69(24):1135-1138.
30. Corona G., Monami M., Rastrelli G., Aversa A., Tishova Y., Saad F., et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011, 1:272-283.
31. Saltevo J., Kautiainen H., Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med 2009, 6(3):463-470.
32. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009, 160:265-273.
33. Richards J.B., Valdes A.M., Burling K., Perks U.C., Spector T.D. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 2007, 92:1517-1523.
34. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Hiroyuki Nagaretani H., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
35. Napoli N., Pedone C., Pozzilli P., Lauretani F., Ferrucci L., Incalzi R.A. Adiponectin and bone mass density: the InCHIANTI study. Bone 2010, 47(6):1001-1005.